Publications by authors named "K Antoniou"
PTEN, a tumor suppressor phosphatase, regulates cellular functions by antagonizing the growth promoting PI3K/Akt/mTOR pathway through the dephosphorylation of the second messenger PIP. Many preclinical cellular and animal studies have used PTEN inhibitors to highlight specific disease contexts where acute activation of PI3K/Akt/mTOR pathway might offer therapeutic advantages. In the present study we have re-evaluated first-generation PTEN inhibitors, including established bisperoxo-vanadium complexes (bpVs).
View Article and Find Full Text PDFRemission of asthma can occur as part of the natural history of the disease; however, the use of biologics can result in disease remission in some patients. In this post hoc analysis of the RELIght study, we aimed to evaluate clinical remission in real life among patients treated with mepolizumab, to detect possible differences between "remitters" and "nonremitters," and to evaluate possible predictors of remission. Clinical remission was defined as the absence of asthma exacerbations, discontinuation of oral corticosteroids (OCS), achievement of asthma control (Asthma Control Test [ACT] ≥ 20), and stable or improved lung function.
View Article and Find Full Text PDFPrevalence of SARS-COV-2 infection and outcomes in Greek sarcoidosis patients.
Sarcoidosis Vasc Diffuse Lung Dis
December 2024
Background And Aim: There is limited data on the prevalence of SARS-COV-2 in sarcoidosis patients and the underlying parameters linked to severity. We aimed to conduct a national multicenter study to explore the prevalence of SARS-COV-2 in sarcoidosis patients and investigate its impact on hospitalization and infection rates, describe the characteristics of the infected population and assess the role of these characteristics in determining the likelihood of infection or hospitalization.
Methods: We recruited all the adult sarcoidosis patients with who were examined across eight Greek Health Interstitial Lung Disease Referral Centers from the beginning of the pandemic until August 1, 2022.
Article Synopsis
- Obstructive sleep apnea (OSA) often occurs alongside idiopathic pulmonary fibrosis (IPF), and specific biomarkers like KL-6, ET-1, and S100A9 may help in diagnosing and understanding the severity of these conditions.
- A study involving 55 participants, including those with IPF and IPF-OSA, measured these biomarker levels and examined their relationship with various health factors.
- Although no significant differences in biomarker levels were found between groups, there were trends suggesting higher ET-1 in IPF-OSA, and significant correlations between KL-6 levels and IPF severity, indicating potential for these biomarkers in identifying OSA impact in IPF patients.
Article Synopsis
- Depression and anxiety are common issues for patients with idiopathic pulmonary fibrosis (IPF), negatively impacting their quality of life, especially during the COVID-19 pandemic.
- A study aimed to evaluate how COVID-19 vaccination affects these mental health issues in IPF patients, using the Hospital Anxiety and Depression Scale (HADS) to measure changes before and after vaccination.
- Results showed a significant improvement in both anxiety and depression scores one month after vaccination, indicating that the vaccine may have beneficial effects on mental health for IPF patients, regardless of factors like age or previous mental health history.